SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001640455-23-000033
Filing Date
2023-03-15
Accepted
2023-03-15 06:21:02
Documents
13
Period of Report
2023-03-14
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K jnce-20230314.htm   iXBRL 8-K 38016
2 EX-99.1 a031520238-kexhibit991.htm EX-99.1 24875
  Complete submission text file 0001640455-23-000033.txt   199839

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT jnce-20230314.xsd EX-101.SCH 1903
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT jnce-20230314_lab.xml EX-101.LAB 23832
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT jnce-20230314_pre.xml EX-101.PRE 12512
7 EXTRACTED XBRL INSTANCE DOCUMENT jnce-20230314_htm.xml XML 4116
Mailing Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 857-259-3840
Jounce Therapeutics, Inc. (Filer) CIK: 0001640455 (see all company filings)

IRS No.: 454870634 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37998 | Film No.: 23733221
SIC: 2836 Biological Products, (No Diagnostic Substances)